Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

Core Insights - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [3] - The company will participate in a fireside chat at the 2025 RBC Capital Markets Healthcare Conference on May 20, 2025 [1] - A live webcast of the event will be available and archived for at least 30 days [2] Company Overview - Design Therapeutics is developing a new class of therapies using its GeneTAC platform, which targets specific disease-causing genes [3] - Current clinical-stage programs include DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy, along with programs for myotonic dystrophy type-1 and Huntington's disease [3] - The company is also engaged in discovery efforts for multiple genomic medicines [3]